Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 25, 2011
Context: This filing serves as a correction to a press release issued on the same date regarding financial results for the three months and year ended December 31, 2010.
Key Financial Metrics
The filing does not provide a full set of financial metrics (revenue, cash flow, debt, etc.) but specifically corrects two figures for the year ended December 31, 2010:
- Income from continuing operations (Corrected): $19,015
- Net income (Corrected): $19,015
- Previously Reported Figures: $19,105 (inadvertently transposed)
Note: The filing text does not provide clear values for revenue, profit margins, cash flow, debt, or liquidity.
Material Changes Versus Prior Period
This report does not discuss operational changes or comparisons to prior periods. The only material change disclosed is the correction of a clerical error in the previously issued press release where the "Income from continuing operations" and "Net income" figures were transposed.
Guidance, Outlook, and Risks
Management Commentary: Management identified that two figures in Exhibit 2 of the original press release were inadvertently transposed. A corrected press release is furnished as Exhibit 99.1.
Risks and Contingencies: No new risks or contingencies are disclosed in this specific filing.
Guidance: No forward-looking guidance is provided in this text.
Important Facts for Investor Verification
- Verify the corrected Net Income and Income from continuing operations for the year ended December 31, 2010, are $19,015, not $19,105.
- Review the corrected press release attached as Exhibit 99.1 for the complete set of financial results.
- Note that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act.